Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE NHL-2 (phase 1b/2). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years, and R2 for up to 12 cycles (28 days per cycle). The primary end point was overall response rate (ORR) per investigator assessment (Lugano criteria). As of 21 September 2024, 108 patients received ≥1 epcoritamab dose in expansion (median follow-up, 28.2 months). Median age was 65 years; 57% had 1 previous line of therapy. ORR and complete response (CR) rate were 96% and 88%, respectively; CR rates in patients with high-risk features were 90% (primary refractory), 82% (refractory to anti-CD20 and an alkylating agent), and 83% (disease progression within 24 months of first-line therapy). Two-year estimates for remaining in CR, progression-free survival, overall survival, and not starting next antilymphoma therapy were 82%, 76%, 90%, and 84%, respectively. Minimal residual disease negativity was observed in 86% of evaluable patients (clonoSEQ assay). Common treatment-emergent adverse events (TEAEs) included neutropenia (65%), COVID-19 (59%), and cytokine release syndrome (CRS; 51%). Grade ≥3 TEAEs occurred in 87% of patients; 5 had grade 5 TEAEs (all COVID-19). CRS events were mostly low grade (grade 1, 38%; grade 2, 11%; grade 3, 2%), all resolved, and none led to epcoritamab discontinuation. Fixed-duration epcoritamab plus R2 demonstrated deep, durable responses with manageable safety and favorable outcomes in R/R FL, irrespective of risk features. This trial was registered at www.ClinicalTrials.gov as #NCT04663347.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Epcoritamab is a subcutaneously administered bispecific antibody approved in numerous countries as monotherapy for follicular lymphoma after two or more lines of therapy.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 33 · Cited by 15
Research works printed but not linked: 2
- Serna, 2025, Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes, Haematologica, 110, 173
- Sehn, 2024, Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND) [abstract], Blood, 144
Metadata
- Authors
- Falchi, L., Sureda, A., Leppä, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Merryman, R. W., Lugtenburg, P. J., Abrisqueta, P., Linton, K. M., Sunkersett, G., Hoehn, D., Rana, A., Abbas, A., Marek, J., Hao, Y., Steele, A. J., Morehouse, C., Hutchings, M., & Belada, D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- University of Helsinki (FI)
- Leiden University Medical Center (NL)
- University Medical Center Groningen (NL)
- Odense University Hospital (DK)
- 7Department of Medicine, Hematology/Oncology, Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA
- Oslo University Hospital (NO)
- Dana-Farber Cancer Institute (US)
- Erasmus MC (NL)
- Vall d'Hebron Hospital Universitari (ES)
- University of Manchester (GB)
- AbbVie (United States) (US)
- Genmab (United States) (US)
- University of Copenhagen (DK)
- Charles University (CZ)
- Corresponding author
- Falchi, Lorenzo
- Belada, David
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2025-11-27
- Volume
- 146
- Issue
- 22
- Pages
- 2629-2640
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC12824663
- OpenAlex
- W4414057143
- Cited by
- 15
- References
- 33
- Citations by year
- 2026: 11 · 2025: 4
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, cc-by-nc-nd)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc-nd)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc-nd)
- Työväentutkimus Vuosikirja (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
- Funders
- Amgen
- AstraZeneca
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- BeiGene
- Incyte
- Seagen
- National Institute for Health and Care Research (NIHR 203308, P30 CA008748)
- Servier
- Swedish Orphan Biovitrum
- MorphoSys
- Ipsen
- National Institutes of Health (CA008748)
- Genentech
- Manchester Biomedical Research Centre (NIHR 203308)
- National Cancer Institute (CA008748, P30CA008748)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Keywords
- epcoritamab, relapsed/refractory follicular lymphoma, rituximab, lenalidomide, overall response rate, complete response, minimal residual disease, cytokine release syndrome, COVID-19 pandemic, neutropenia, progression-free survival, high-risk features
- MeSH terms
- Rituximab, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neoplasm Recurrence, Local, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. https://app.cochat.ai/papers/10.1182/blood.2025029909
- The paper
- Falchi, L., Sureda, A., Leppä, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Merryman, R. W., Lugtenburg, P. J., Abrisqueta, P., Linton, K. M., Sunkersett, G., Hoehn, D., Rana, A., Abbas, A., Marek, J., Hao, Y., Steele, A. J., . . . Belada, D. (2025). Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. https://doi.org/10.1182/blood.2025029909
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.